Search for: "L&P Manufacturing, Inc." Results 81 - 100 of 368
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Jul 2018, 10:19 am by Lawrence B. Ebert
Thereafter ZUP and Keith Parten, Presidentand CEO of Nash Manufacturing, Inc. [read post]
20 Jul 2018, 8:59 am by Camilla Alexandra Hrdy
As the Court explained in Kewanee, without trade secret protection,"[t]he holder of a trade secret would not likely share his secret with a manufacturer who cannot be placed under binding legal obligation to pay a license fee or to protect the secret. [read post]
27 Jun 2018, 9:13 am by Kevin Kaufman
They are intended to increase consumption of goods manufactured at home by increasing the price of foreign-produced goods. [1]   Generally, tariffs result in consumers paying more for goods than they would have otherwise in order to prop up industries at home. [read post]
21 May 2018, 9:02 pm by News Desk
The complaint alleges that FDA inspections found Listeria monocytogenes (L. mono) at the companies’ facility and that the defendants failed to put in place adequate measures to reduce the risk of health hazards such as L. mono, Clostridium botulinum, and scombrotoxin. [read post]
11 May 2018, 7:22 am by admin
By the time federal regulators finally took control of Lincoln in 1989, the S&L was insolvent. [read post]
14 Jan 2018, 6:34 am
(Wyeth, 555 U.S. at p. 578; see id. at p. 579 [“State tort suits uncover unknown drug hazards and provide incentives for drug manufacturers to disclose safety risks promptly. [read post]
13 Jan 2018, 8:00 pm
Wyeth, Inc., 850 N.W.2d at p. 371 (plur. opn. of Waterman, J.) [read post]
9 Jan 2018, 3:00 am by Ed. Microjuris.com Puerto Rico
El 24 de junio de 2014, el señor González Cabán y varios de sus familiares presentaron una demanda en daños y perjuicios ante el Tribunal de Distrito de Estados Unidos para el Distrito de Puerto Rico contra: (1)JR Seafood Inc.,(2) Integrand Insurance Company; (3) Packers Provisions of Puerto Rico Inc. [read post]
26 Dec 2017, 7:08 pm by Ben Vernia
In another important case, drug manufacturer Mylan Inc. paid approximately $465 million to resolve allegations that it underpaid rebates owed under the Medicaid Drug Rebate Program by erroneously classifying its patented, brand name drug EpiPen – which has no therapeutic equivalents or generic competition – as a generic drug to avoid its obligation to pay higher rebates. [read post]